<DOC>
	<DOCNO>NCT01333852</DOCNO>
	<brief_summary>Metformin plus paclitaxel recurrent metastatic head neck cancer : randomize phase II trial</brief_summary>
	<brief_title>Metformin Plus Paclitaxel Metastatic Recurrent Head Neck Cancer</brief_title>
	<detailed_description>METTAX phase II randomize trial aim evaluate addition metformin paclitaxel patient fail curative-intent treatment Head-and neck neoplasm . Patients eligible protocol randomize paclitaxel 175mg/m2 plus metformin placebo disease progression unacceptable toxicity . The primary end-point disease control ( complete response , partial response stable disease , accord RECIST 1.1 ) 12th week . Secondary end-points PFS , OS , response rate safety . Molecular marker sample collect treatment test correlation clinical outcome .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>18 year old Biopsyproven head neck squamous cell carcinoma Ineligibility curative intent therapy , e.g. , surgery radiation therapy recurrent stage IV disease previous failure platinumbased chemotherapy measurable disease accord RECIST v1.1 PS ECOG 02 know hypersensitivity metformin paclitaxel SNC metastasis Acute chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>metformin</keyword>
	<keyword>squamous cell carcinoma</keyword>
</DOC>